Among 19 analysts covering SAGE Therapeutics (NASDAQ:SAGE), 17 have Buy rating, 0 Sell and 2 Hold. Therefore 89% are positive. SAGE Therapeutics had 60 analyst reports since September 3, 2015 according to SRatingsIntel. Needham maintained Sage Therapeutics, Inc. (NASDAQ:SAGE) rating on Tuesday, September 12. Needham has “Buy” rating and $86.0 target. The stock has “Buy” rating by Cowen & Co on Thursday, December 7. As per Tuesday, June 13, the company rating was maintained by Needham. The firm has “Buy” rating by H.C. Wainwright given on Thursday, June 23. The stock of Sage Therapeutics, Inc. (NASDAQ:SAGE) earned “Neutral” rating by Goldman Sachs on Wednesday, March 30. The stock of Sage Therapeutics, Inc. (NASDAQ:SAGE) earned “Buy” rating by SunTrust on Tuesday, February 27. RBC Capital Markets maintained Sage Therapeutics, Inc. (NASDAQ:SAGE) rating on Monday, October 16. RBC Capital Markets has “Buy” rating and $117.0 target. H.C. Wainwright downgraded the shares of SAGE in report on Wednesday, February 22 to “Neutral” rating. The stock has “Buy” rating by Canaccord Genuity on Friday, August 4. Chardan Capital Markets upgraded Sage Therapeutics, Inc. (NASDAQ:SAGE) on Thursday, December 7 to “Buy” rating. See Sage Therapeutics, Inc. (NASDAQ:SAGE) latest ratings:
13/06/2018 Broker: Canaccord Genuity Old Rating: Buy New Rating: Buy Old Target: $210 New Target: $220 Maintain
06/06/2018 Broker: Ladenburg Thalmann Rating: Buy New Target: $230 Initiates Coverage On
22/05/2018 Broker: Chardan Capital Markets Rating: Buy New Target: $225.0000 Upgrade
23/04/2018 Broker: BMO Capital Markets Rating: Buy New Target: $203.0000 Maintain
26/03/2018 Broker: Canaccord Genuity Rating: Buy New Target: $210.0000 Maintain
27/02/2018 Broker: SunTrust Rating: Buy New Target: $203.0 Maintain
26/02/2018 Broker: Morgan Stanley Rating: Overweight New Target: $225 Initiates Coverage On
22/02/2018 Broker: RBC Capital Markets Rating: Buy New Target: $277.0 Maintain
31/01/2018 Broker: BMO Capital Markets Rating: Buy New Target: $203.0 Maintain
Boston Common Asset Management Llc increased Novartis A G Sponsored Adr (NVS) stake by 5.88% reported in 2018Q1 SEC filing. Boston Common Asset Management Llc acquired 7,854 shares as Novartis A G Sponsored Adr (NVS)’s stock declined 11.54%. The Boston Common Asset Management Llc holds 141,383 shares with $11.43 million value, up from 133,529 last quarter. Novartis A G Sponsored Adr now has $193.70B valuation. The stock increased 1.46% or $1.08 during the last trading session, reaching $75.06. About 1.74M shares traded or 3.96% up from the average. Novartis AG (NYSE:NVS) has declined 6.45% since June 24, 2017 and is downtrending. It has underperformed by 19.02% the S&P500. Some Historical NVS News: 27/03/2018 – Novartis sells stake in consumer business to GSK for $13bn; 06/03/2018 – Novartis’ Xolair(R) recommended in new global chronic urticaria guideline; 18/04/2018 – Conatus Pharmaceuticals’ IDN-7314 Pan-caspase Inhibitor Reduces Hepatic Tissue Factor-Driven Coagulation In Vitro and In Vivo; 30/04/2018 – Novartis receives FDA approval of Tafinlar® + Mekinist® for adjuvant treatment of BRAF V600-mutant melanoma; 09/04/2018 – Novartis in $8.7bn bet […]; 09/04/2018 – NOVARTIS DOESN’T HAVE AN OUT IF THERE IS UNEXPECTED AVXS EVENT; 16/05/2018 – NOVARTIS AG NOVN.S CEO SAYS “LOOKING HARD” AT U.S. SOLID GENERICS BUSINESS AT SANDOZ; 10/05/2018 – FiercePharma: Trump’s lawyer offered Novartis a doorway to the president, and ex-CEO Jimenez accepted, insiders say; 28/05/2018 – NOVARTIS: IMPROVEMENT IN QUALITY OF LIFE DOMAINS WITH ENTRESTO®; 16/05/2018 – NOVARTIS AG NOVN.S CEO SAYS FIRM MADE MISTAKES RECENTLY AND WORLD RIGHTLY EXPECTS MORE FROM A LEADING HEALTHCARE COMPANY
Among 17 analysts covering Novartis Ag (NYSE:NVS), 5 have Buy rating, 3 Sell and 9 Hold. Therefore 29% are positive. Novartis Ag had 38 analyst reports since July 28, 2015 according to SRatingsIntel. Cowen & Co maintained it with “Hold” rating and $9000 target in Wednesday, August 9 report. HSBC downgraded the stock to “Hold” rating in Tuesday, May 29 report. The stock of Novartis AG (NYSE:NVS) earned “Sell” rating by Barclays Capital on Wednesday, October 25. The rating was maintained by Cowen & Co with “Hold” on Monday, September 11. The stock has “Neutral” rating by Credit Suisse on Friday, May 25. The stock of Novartis AG (NYSE:NVS) has “Neutral” rating given on Tuesday, March 29 by Citigroup. The stock of Novartis AG (NYSE:NVS) has “Market Perform” rating given on Monday, October 23 by Leerink Swann. The firm has “Neutral” rating given on Friday, June 16 by J P Morgan Chase Co. Cowen & Co downgraded Novartis AG (NYSE:NVS) on Wednesday, April 5 to “Market Perform” rating. The stock of Novartis AG (NYSE:NVS) has “Hold” rating given on Friday, February 2 by Cowen & Co.
Boston Common Asset Management Llc decreased Avangrid Inc Com stake by 14,240 shares to 137,932 valued at $7.05M in 2018Q1. It also reduced 8Point3 Energy Partners Lp stake by 310,462 shares and now owns 81,815 shares. Cme Group Inc Com (NASDAQ:CME) was reduced too.
More notable recent Novartis AG (NYSE:NVS) news were published by: Nasdaq.com which released: “Long-Term Investors Take Note — These 5 Big Pharma Companies Have the Best Pipelines” on June 24, 2018, also Seekingalpha.com with their article: “Novartis: Exit Sandoz US Now” published on June 06, 2018, Seekingalpha.com published: “Novartis’ Kymriah shows sustained benefit in DLBCL patients” on June 18, 2018. More interesting news about Novartis AG (NYSE:NVS) were released by: Streetinsider.com and their article: “Novartis (NVS) Granted FDA Approval for Inclusion of New Evidence that Cosentyx (secukinumab) Inhibits Progression …” published on June 19, 2018 as well as Seekingalpha.com‘s news article titled: “Breaking Down Barriers: BiOasis Technologies Promises Breakthrough Brain Drug Delivery” with publication date: June 19, 2018.
The stock decreased 4.83% or $7.78 during the last trading session, reaching $153.46. About 1.20 million shares traded or 104.48% up from the average. Sage Therapeutics, Inc. (NASDAQ:SAGE) has risen 127.92% since June 24, 2017 and is uptrending. It has outperformed by 115.35% the S&P500. Some Historical SAGE News: 08/05/2018 – Sage Business Cloud Customers to Benefit from Faster lnvoicing with Extended Microsoft Integration; 21/05/2018 – Account Management Giant Sage and B4B Payments Announce Key Strategic Partnership; 27/03/2018 – FORTUNE Magazine and Great Places to Work Name Sage’s San Jose Sage lntacct Office One of the Bay Area’s Best Workplaces; 30/03/2018 – Watercrest Senior Living Group Welcomes Jennifer Lopez as Community Relations Director of Sage Park Assisted Living and Memory; 23/05/2018 – SAGE INTEGRATES PAYPAL TO HELP BUILDERS GET PAID FASTER; 13/04/2018 – Sage Group PLC Sees Trading Below Views; 18/04/2018 – CEdMA Honors Sage as Leader in Educational Services With 2018 Impact Award; 14/03/2018 – Delos Capital Acquires Sage Metals Limited; 15/03/2018 – UCSF and Sage Bionetworks Announce Stress Research Study Leveraging New Sensor Technologies on the Samsung Galaxy S9 and S9+; 30/04/2018 – LEBARA SAYS NEW CFO OLIVIER SAGE WILL JOIN FROM MID MAY
More notable recent Sage Therapeutics, Inc. (NASDAQ:SAGE) news were published by: Nasdaq.com which released: “Here’s Why Sage Therapeutics Rose as Much as 20.3% Today” on June 12, 2018, also Benzinga.com with their article: “Analyst: Sage Therapeutics Holds A Breakthrough In Depression Treatment” published on June 08, 2018, Businesswire.com published: “Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)” on June 04, 2018. More interesting news about Sage Therapeutics, Inc. (NASDAQ:SAGE) were released by: Nasdaq.com and their article: “Market Trends Toward New Normal in Cheniere Energy Partners, LP, UnitedHealth Group, Anthem, Sage Therapeutics …” published on June 12, 2018 as well as Schaeffersresearch.com‘s news article titled: “Upbeat Drug Data Has Galmed Stock Scaling Nasdaq” with publication date: June 12, 2018.
Investors sentiment increased to 1.73 in 2018 Q1. Its up 0.24, from 1.49 in 2017Q4. It improved, as 22 investors sold Sage Therapeutics, Inc. shares while 56 reduced holdings. 47 funds opened positions while 88 raised stakes. 45.19 million shares or 9.02% more from 41.45 million shares in 2017Q4 were reported. Lord Abbett & Limited Liability Corporation reported 467,854 shares stake. Zurcher Kantonalbank (Zurich Cantonalbank) has 0% invested in Sage Therapeutics, Inc. (NASDAQ:SAGE) for 2,827 shares. 43,000 are held by State Of Wisconsin Inv Board. Castleark Mngmt Limited Liability Co owns 23,076 shares. Teacher Retirement Of Texas has 0.01% invested in Sage Therapeutics, Inc. (NASDAQ:SAGE). The New York-based State Common Retirement Fund has invested 0.03% in Sage Therapeutics, Inc. (NASDAQ:SAGE). Artal Sa invested in 100,000 shares. Macquarie Group Limited invested in 2,824 shares or 0% of the stock. Guggenheim Cap Ltd Liability Corp reported 0.02% stake. Point72 Asset Management L P holds 0.07% of its portfolio in Sage Therapeutics, Inc. (NASDAQ:SAGE) for 102,600 shares. California State Teachers Retirement stated it has 64,147 shares. Mckinley Mgmt Limited Co Delaware holds 0% in Sage Therapeutics, Inc. (NASDAQ:SAGE) or 475 shares. Teachers Retirement System Of The State Of Kentucky, Kentucky-based fund reported 27,794 shares. Td Asset Mngmt accumulated 131,883 shares or 0.03% of the stock. Smith Asset Mgmt Group Inc L P holds 0.02% in Sage Therapeutics, Inc. (NASDAQ:SAGE) or 4,460 shares.
Sage Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system disorders. The company has market cap of $7.14 billion. The Company’s lead product candidate includes SAGE-547, a proprietary intravenous formulation of allopregnanolone that is in Phase III clinical development as an adjunctive therapy for the treatment of super-refractory status epilepticus , as well as for the treatment of post-partum depression (PPD). It currently has negative earnings. The companyÂ’s product pipeline includes SAGE-217, a novel neuroactive steroid, which is in Phase II clinical trials for the treatment of PPD, major depressive disorders, essential tremor, and ParkinsonÂ’s diseases; and SAGE-689 a novel positive allosteric modulator of GABAA receptors that is in preclinical stage for the treatment of status epilepticus.
Since January 10, 2018, it had 0 buys, and 5 insider sales for $32.85 million activity. The insider PAUL STEVEN M sold $10.00M. FRATES JAMES M sold $1.08M worth of Sage Therapeutics, Inc. (NASDAQ:SAGE) on Tuesday, May 8. On Wednesday, January 10 Kanes Stephen sold $7.80 million worth of Sage Therapeutics, Inc. (NASDAQ:SAGE) or 44,000 shares. $9.96M worth of Sage Therapeutics, Inc. (NASDAQ:SAGE) was sold by STARR KEVIN P. Another trade for 28,153 shares valued at $4.02M was sold by IGUCHI KIMI.